BRISTOL-MYERS SQUIBB GLUCOPHAGE 1996 SALES TARGET IS $200 MIL., COMPANY TELLS ANALYSTS; COST-CUTTING MOVES ARE PROJECTED TO SAVE $1.1 BIL. TO $1.5 BIL. BY 1998
Executive Summary
Bristol-Myers Squibb's Glucophage (metformin) could reach 1996 sales of $200 mil., the company told securities analysts Dec. 11.